coronary stenosis

The Best of Main Arena, day 1

The Best of the SOLACI-SOCIME 2022 Main Arena: Complex PCI Guided by Intravascular Imaging

In the first session of SOLACI-SOCIME 2022 on “Complex angioplasty guided by intravascular imaging”, Dr. Alejandro Diaz (MEX) reviewed the evidence on intravascular ultrasound (IVUS) in complex angioplasties. A meta-analysis indicated its use is associated with a significant decrease in the risk of death, acute myocardial infarction (AMI), and new target lesion revascularization (TLR) in<a href="https://solaci.org/en/2022/08/09/the-best-of-the-solaci-socime-2022-main-arena-complex-pci-guided-by-intravascular-imaging/" title="Read more" >...</a>

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on<a href="https://solaci.org/en/2022/08/06/cto-trials-vs-real-world/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

Thin vs. Ultrathin Stents: 1-Year Clinical Results After IVUS/OCT-Guided Implantation

Second generation drug-eluting stents have lower frequency of thrombotic complications and in-stent restenosis. While clinical results have significantly improved, having a 2-3% annual rate of these complications within the first year after angioplasty is still worrisome. This resulted in the development of stents with struts &lt;70 µm (ultrathin), with bioresorbable polymer and abluminal cover. Stents<a href="https://solaci.org/en/2022/07/20/thin-vs-ultrathin-stents-1-year-clinical-results-after-ivus-oct-guided-implantation/" title="Read more" >...</a>

¿Es frecuente el uso de IVUS para guiar la ATC?

Is IVUS Guided PCI a Common Technique?

We all know the benefits of ultravascular ultrasound (IVUS) in the development of percutaneous coronary intervention, such as more accurate vessel measurement, improved stent expansion and apposition, and complication identification. This is why the use of IVUS is a class IIa recommendation in AHA and ESC guidelines.&nbsp; The aim of this retrospective study was to<a href="https://solaci.org/en/2022/07/06/is-ivus-guided-pci-a-common-technique/" title="Read more" >...</a>

El FFR ahorra síntomas a los pacientes y costos a los financiadores de salud

FFR and IFR: Are We Talking About the Same Thing?

To evaluate borderline coronary lesions (a 40% to 70% obstruction), determining associated ischemia is paramount. For this purpose, pressure gradients are measured across the stenosis. These measurements can be hyperemic, such as the fractional flow reserve (FFR), or taken at rest, such as the instantaneous wave-free ratio (iFR). According to the iFR-SWEDEHEART 5-year follow-up outcomes,<a href="https://solaci.org/en/2022/06/14/ffr-and-ifr-are-we-talking-about-the-same-thing/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel. Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons. The aim of this randomized, multicenter study was to evaluate<a href="https://solaci.org/en/2022/06/13/using-biolimus-coated-balloons-for-treating-small-vessel-disease-yields-promising-results/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>

SOLACI Presente en PCR y en SCAI 2022

SOLACI Present at the Main Interventional Cardiology Meetings in the World

Once more, the Latin American Society of Interventional Cardiology (SOLACI) will attend two of the most important annual meetings in the field: the EuroPCR 2022 and the SCAI 2022 Scientific Sessions. The society will take part in with 2 challenging joint sessions to shar the Latin American reality in different areas of interest within the<a href="https://solaci.org/en/2022/05/16/solaci-present-at-the-main-interventional-cardiology-meetings-in-the-world/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Avatar Trial: Is It Time to Use Surgical Aortic Valve Replacement in Asymptomatic Patients?

It is still unclear whether surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis (AS) and conserved left ventricular function (C1 indication according to AHA guidelines). The European American guidelines only recommend intervention in asymptomatic patient when there is ventricular compromise (ejection fraction &lt;50%, class I indication) or with a<a href="https://solaci.org/en/2022/05/05/avatar-trial-is-it-time-to-use-surgical-aortic-valve-replacement-in-asymptomatic-patients/" title="Read more" >...</a>

Resonancia vs FFR en lesiones no culpables del infarto

OCT in STEMI Patients: Is It Safe to Prevent Stenting?

Percutaneous coronary intervention in patients with acute myocardial infarction (AMI) where the physiopathological mechanism is plaque erosion or non-atherosclerotic mechanisms (such as spontaneous coronary artery dissection) is not beneficial according to recent studies.&nbsp; The EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography–Based Management in Plaque Erosion) has shown medical treatment with no<a href="https://solaci.org/en/2022/04/20/oct-in-stemi-patients-is-it-safe-to-prevent-stenting/" title="Read more" >...</a>

Top